Long-term results (>5 years) for synthetic substances used to repair facial lipoatrophy have not been published. We performed a cross-sectional study to evaluate the 10-year safety of polyacrylamide hydrogel (Aquamid) among the 751 patients from our unit who received facial infiltrations at least 10 years ago. Epidemiological and clinical data such as complications and patient satisfaction were collected. We also identified those patients who presented a facial infection at any time after infiltration. A total of 104 patients had received Aquamid at least 10 years ago. Before infiltrations, 24.0%, 41.3%, and 34.7% presented very severe, severe, and moderate facial lipoatrophy, respectively. After a mean (SD) of 10.3 (0.5) years since the infiltrations, 19.2%, 47.7%, and 31.7% of patients reported moderate, mild, and no signs of facial lipoatrophy. The values reported by physicians for the same categories were 1.9%, 10.6%, and 87.5%. Indurations were detected in 6.7% of patients and nodules in 3.8%. Five patients (4.8%) had a local infection. A further 15 patients with a shorter follow-up (less than 10 years) presented local infections (overall incidence considering the 751 patients who received infiltrations of Aquamid, 2.7%); the product had to be withdrawn in three cases. The majority of patients were highly satisfied (74.8%) or satisfied (23.4%) with the cosmetic results; among patients with severe or very severe lipoatrophy at baseline, 31.4% were satisfied and 65.7% were highly satisfied. Infiltrations with polyacrylamide hydrogel (Aquamid) are a safe strategy for the treatment of facial lipoatrophy in the long term. The rate of severe complications was low, and patient satisfaction with the cosmetic results was high. However, facial infections may appear in the long term. Therefore, HIV-infected patients who received synthetic substances should be carefully monitored over time.

Download full-text PDF

Source
http://dx.doi.org/10.1089/AID.2015.0004DOI Listing

Publication Analysis

Top Keywords

facial lipoatrophy
20
patients
12
patients received
12
safety polyacrylamide
8
facial
8
hiv-infected patients
8
synthetic substances
8
polyacrylamide hydrogel
8
hydrogel aquamid
8
751 patients
8

Similar Publications

Ptosis in human immunodeficiency virus-infected patients under long-term antiretroviral treatment.

Clin Neurol Neurosurg

December 2024

Department of Neurosciences and Mental Health, Unidade Local de Saúde de Santa Maria, Lisbon, Portugal; Faculdade de Medicina-Instituto de Medicina Molecular, Centro de Estudos Egas Moniz, Universidade de Lisboa, Lisbon, Portugal.

Objective: To present cases of ptosis in HIV-1 patients on long-term antiretroviral therapy (ART) and review the existing literature.

Methods: Five HIV-1-positive patients with slowly progressive bilateral ptosis underwent a comprehensive diagnostic evaluation, including imaging studies, neurophysiological testing, muscle biopsy, and genetic analysis. A literature review was conducted.

View Article and Find Full Text PDF

Case Report: Concurrent pathogenic variants in the gene as a cause of sporadic partial lipodystrophy.

Front Genet

November 2024

Department of Nutrition, Diabetes and Metabolism, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.

Introduction: Inherited lipodystrophies are a group of rare diseases defined by severe reduction in adipose tissue mass and classified as generalized or partial. We report a non-familial (sporadic) case of partial lipodystrophy caused by a novel genetic mechanism involving closely linked pathogenic variants in the gene.

Methods: A female adult with partial lipodystrophy and her parents were evaluated for gene variants across the exome under different mendelian inheritance models (autosomal dominant, recessive, compound heterozygous, and X-linked) to find pathogenic variants.

View Article and Find Full Text PDF

Current status and perspectives in the treatment of facial lipoatrophy in HIV-positive patients in 2024.

Ann Chir Plast Esthet

December 2024

Service de chirurgie plastique, réparatrice, esthétique, hôpital Cavale-Blanche, Brest, France.

Facial lipoatrophy, a sign of normal aging, also occurs due to lipodystrophy from metabolic disorders affecting lipogenesis. It can be hereditary or acquired, localized or generalized. In HIV patients, prolonged antiretroviral therapy (ART) is a major cause, affecting around 55% of patients with 47% experiencing facial lipoatrophy.

View Article and Find Full Text PDF
Article Synopsis
  • Lupus panniculitis is a chronic form of cutaneous lupus that causes painful, firm nodules on areas like the legs, face, and trunk, potentially leading to scarring or loss of fat in those areas.
  • Patients suffering from lipoatrophy due to lupus panniculitis may experience distress, and there is varying information on treating it with fat transfer or fillers.
  • A case study highlights a 37-year-old woman who successfully restored volume in her right cheek using injectable hyaluronic acid filler after experiencing lipoatrophy following a period of stable disease.
View Article and Find Full Text PDF

Treatment of facial lipodystrophy induced by a biologic agent (IPD-1): a literature review.

Einstein (Sao Paulo)

December 2024

Division of Plastic Surgery, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.

Agents that inhibit programmed cell death (IPD-1) in T lymphocytes are indicated for patients with advanced cancer. However, some individuals may develop endocrinological conditions, such as diabetes, thyroid dysfunction, and lipodystrophy, after treatment. This systematic review and case report of IPD-1 lipodystrophies describes a patient who received nivolumab treatment for advanced clear cell renal carcinoma and subsequently developed diabetes as well as facial and body lipodystrophy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!